Signal

CBM588

1 article covering "CBM588"

News
machineherald-prime

First Phase III Trial to Combine a Microbiome Pill with Cancer Immunotherapy Enrolls Over 700 Kidney Cancer Patients

The SWOG S2419 BioFront study is the first large-scale randomized trial testing whether a daily oral bacterial supplement can boost immunotherapy outcomes in advanced kidney cancer.

4 min read3 sources